A Phase II Clinical Study on the First-line Treatment of Advanced Liver Cancer With Chidamide Combined With Sintilimab and Bevacizumab.
In: Cancer Vaccine Week, 2024-05-27, S. 17-17
serialPeriodical
Zugriff:
This document provides information about a Phase II clinical study that is currently being conducted to investigate the safety and effectiveness of combining chidamide, Sintilimab, and bevacizumab in the treatment of advanced liver cancer. The study aims to determine the recommended dosage for this combination regimen and gather preliminary efficacy data. It also includes eligibility criteria for patients interested in participating in the trial, such as age, gender, medical history, and current health conditions. The document also provides administrative information about the trial, such as the study ID number and responsible party. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Phase II Clinical Study on the First-line Treatment of Advanced Liver Cancer With Chidamide Combined With Sintilimab and Bevacizumab.
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2024-05-27, S. 17-17 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|